Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease

Genetics in Medicine

Volumn 14, Issue 1, 2012, Pages 135-142

  Messinger, Yoav H ^a   Mendelsohn, Nancy J ^a   Rhead, William ^b   Dimmock, David ^b   Hershkovitz, Eli ^c   Champion, Michael ^d   Jones, Simon A ^e   Olson, Rebecca ^a   White, Amy ^b   Wells, Cara ^b   Bali, Deeksha ^f   Case, Laura E ^f   Young, Sarah P ^f   Rosenberg, Amy S ^g   Kishnani, Priya S ^f  

^a CHILDREN S HOSPITALS AND CLINICS OF MINNESOTA   (United States)

^b CHILDREN S HOSPITAL OF WISCONSIN   (United States)

^c BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^d EVELINA LONDON CHILDREN S HOSPITAL   (United Kingdom)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

^g CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

immune tolerance; methotrexate; Pompe disease; rituximab

Indexed keywords

IMMUNOGLOBULIN; METHOTREXATE; RECOMBINANT GLUCAN 1,4 ALPHA GLUCOSIDASE; RITUXIMAB;

ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; CASE REPORT; ENZYME REPLACEMENT; GLYCOGEN STORAGE DISEASE TYPE 2; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; INFANT; TREATMENT DURATION; TREATMENT RESPONSE;

ALPHA-GLUCOSIDASES; ANTIBODIES; B-LYMPHOCYTES; ENZYME REPLACEMENT THERAPY; FEMALE; GLYCOGEN STORAGE DISEASE TYPE II; HUMANS; IMMUNE TOLERANCE; INFANT; INFANT, NEWBORN; MAGNETIC RESONANCE IMAGING; MALE; NEUROIMAGING; OLIGOSACCHARIDES; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 84855542158     PISSN: 10983600     EISSN: 15300366     Source Type: Journal    
DOI: 10.1038/gim.2011.4     Document Type: Article

References (27)

1. Kishnani PS, Howell RR. Pompe disease in infants and children. J Pediatr 2004;144(suppl 5):S35-S43. (Pubitemid 38591273)
2. Amalfitano A, Bengur AR, Morse RP, et al. Recombinant human acid alphaglucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. Genet Med 2001;3:132-138.
3. Kishnani PS, Corzo D, Nicolino M, et al. Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 2007;68:99-109. (Pubitemid 46071892)
4. Kishnani PS, Goldenberg PC, DeArmey SL, et al. Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol Genet Metab 2010;99:26-33.
5. Mendelsohn NJ, Messinger YH, Rosenberg AS, Kishnani PS. Elimination of antibodies to recombinant enzyme in Pompe's disease. N Engl J Med 2009;360:194-195.
6. Kishnani PS, Nicolino M, Voit T, et al. Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease. J Pediatr 2006;149:89-97. (Pubitemid 44081924)
7. Young SP, Zhang H, Corzo D, et al. Long-term monitoring of patients with infantile-onset Pompe disease on enzyme replacement therapy using a urinary glucose tetrasaccharide biomarker. Genet Med 2009;11:536-541.
8. Brooks DA. Immune response to enzyme replacement therapy in lysosomal storage disorder patients and animal models. Mol Genet Metab 1999;68:268-275. (Pubitemid 29501099)
9. Wang J, Lozier J, Johnson G, et al. Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment. Nat Biotechnol 2008;26:901-908.
10. Antonarakis SE, Rossiter JP, Young M, et al. Factor VIII gene inversions in severe hemophilia A: results of an international consortium study. Blood 1995;86:2206-2212.
11. Kakkis ED, Muenzer J, Tiller GE, et al. Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med 2001;344:182-188. (Pubitemid 32064139)
12. Linthorst GE, Hollak CE, Donker-Koopman WE, Strijland A, Aerts JM. Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta. Kidney Int 2004;66:1589-1595. (Pubitemid 39298394)
13. Warrier I, Ewenstein BM, Koerper MA, et al. Factor IX inhibitors and anaphylaxis in hemophilia B. J Pediatr Hematol Oncol 1997;19:23-27. (Pubitemid 27124054)
14. Wraith JE, Beck M, Lane R, et al. Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-L-iduronidase (laronidase). Pediatrics 2007;120:e37-e46. (Pubitemid 47036214)
15. Banugaria SG, Prater SN, Ng YK, et al. The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease. Genet Med 2011;13:729-736.
16. Smith KG, Jones RB, Burns SM, Jayne DR. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment. Arthritis Rheum 2006;54:2970-2982. (Pubitemid 44497778)
17. Chuansumrit A, Husapadol S, Wongwerawattanakoon P, Hongeng S, Sirachainan N, Pakakasama S. Rituximab as an adjuvant therapy to immune tolerance in a haemophilia A boy with high inhibitor titre. Haemophilia 2007;13:108-110. (Pubitemid 46002356)
18. Biss TT, Velangi MR, Hanley JP. Failure of rituximab to induce immune tolerance in a boy with severe haemophilia A and an alloimmune factor VIII antibody: a case report and review of the literature. Haemophilia 2006;12:280-284.
19. Carcao M, St Louis J, Poon MC, et al. Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience. Haemophilia 2006;12:7-18.
20. Hay C, Recht M, Carcao M, Reipert B. Current and future approaches to inhibitor management and aversion. Semin Thromb Hemost 2006;32 (suppl 2):15-21.
21. Stasi R, Cooper N, Del Poeta G, et al. Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. Blood 2008;112:1147-1150.
22. Rohrbach M, Klein A, Köhli-Wiesner A, et al. CRIM-negative infantile Pompe disease: 42-month treatment outcome. J Inherit Metab Dis 2010;33:751-757.
23. Nimmerjahn F, Ravetch JV. Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol 2008;26:513-533. (Pubitemid 351600384)
24. Anthony RM, Wermeling F, Karlsson MC, Ravetch JV. Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc Natl Acad Sci USA 2008;105:19571-19578.
25. Carson KR, Focosi D, Major EO, et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol 2009;10:816-824.
26. Joseph A, Munroe K, Housman M, Garman R, Richards S. Immune tolerance induction to enzyme-replacement therapy by co-administration of short-term, low-dose methotrexate in a murine Pompe disease model. Clin Exp Immunol 2008;152:138-146. (Pubitemid 351347554)
27. Desnick RJ. Enzyme replacement and enhancement therapies for lysosomal diseases. J Inherit Metab Dis 2004;27:385-410. (Pubitemid 38756323)